Crossmark

Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers

Crossref DOI link: https://doi.org/10.1186/s13054-020-02946-y

Published Online: 2020-06-01

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Borges, Isabela http://orcid.org/0000-0002-9684-9353
Carneiro, Rafael

Bergo, Rafael

Martins, Larissa

Colosimo, Enrico

Oliveira, Carolina

Saturnino, Saulo

Andrade, Marcus Vinícius

Ravetti, Cecilia

Nobre, Vandack
Funding

Funding for this research was provided by:

Fundação de Amparo à Pesquisa do Estado de Minas Gerais (APQ- 00365-10)
License Information

Text and Data Mining valid from 2020-06-01

Version of Record valid from 2020-06-01
More Information

Article History

Received: 17 February 2020

Accepted: 5 May 2020

First Online: 1 June 2020

Ethics approval and consent to participate

: The study was approved by the Ethics Committee of the <i>Universidade Federal de Minas Gerais</i>, approval protocol number 53351416.9.0000.5149, and all inclusions required signing of an informed consent form by the patient or surrogate.

: All authors consent to the publication of the manuscript in <i>Critical Care</i>, should the article be accepted by the Editor-in-chief upon completion of the refereeing process.

: The authors have disclosed that they do not have any conflicts of interest.

Document is current

Any future updates will be listed below